hydroxyurea has been researched along with Sepsis in 5 studies
Sepsis: Systemic inflammatory response syndrome with a proven or suspected infectious etiology. When sepsis is associated with organ dysfunction distant from the site of infection, it is called severe sepsis. When sepsis is accompanied by HYPOTENSION despite adequate fluid infusion, it is called SEPTIC SHOCK.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Hydroxyurea has been shown to reduce leukocyte counts, decrease inflammatory cytokines, and limit organ inflammation in ischemia-reperfusion models." | 8.12 | The effects of hydroxyurea on proinflammatory cytokine and tissue histopathology in an experimental sepsis model. ( Ergil, J; Kulturoglu, G; Kulturoglu, MO; Onder, EO; Yalcindag, A, 2022) |
| " Hydroxyurea has been shown to reduce leukocyte counts, decrease inflammatory cytokines, and limit organ inflammation in ischemia-reperfusion models." | 4.12 | The effects of hydroxyurea on proinflammatory cytokine and tissue histopathology in an experimental sepsis model. ( Ergil, J; Kulturoglu, G; Kulturoglu, MO; Onder, EO; Yalcindag, A, 2022) |
| " Our results, while no longer the product of a randomized study because of the ethical concerns of withholding an efficacious treatment, suggest that long-term use of hydroxyurea is safe and might decrease mortality." | 2.75 | The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up. ( Armstrong, FD; Ataga, K; Ballas, SK; Castro, O; DeCastro, L; Kutlar, A; McCarthy, WF; Smith, W; Steinberg, MH; Swerdlow, P; Waclawiw, MA, 2010) |
| "Hydroxyurea therapy was used in 30 patients (31." | 1.36 | Sickle cell disease from Africa to Belgium, from neonatal screening to clinical management. ( Cotton, F; Dedeken, L; Dresse, MF; Ferster, A; Gulbis, B; Heijmans, C; Ketelslegers, O; Lê, PQ; Vanderfaeillie, A; Vermylen, C; Vertongen, F, 2010) |
| "Despite treatment for pulmonary hypertension and provision of respiratory support, the patient died." | 1.33 | Pulmonary hypertension in a child with juvenile myelomonocytic leukemia secondary to pulmonary leukemic cell infiltration. ( Alioglu, B; Demirhan, B; Erbay, A; Ozbek, N; Ozyurek, E; Varan, B, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kulturoglu, G | 1 |
| Ergil, J | 1 |
| Kulturoglu, MO | 1 |
| Yalcindag, A | 1 |
| Onder, EO | 1 |
| Bandyopadhyay, D | 1 |
| Manna, S | 1 |
| Hajra, A | 1 |
| Bhattacharya, TD | 1 |
| Steinberg, MH | 1 |
| McCarthy, WF | 1 |
| Castro, O | 1 |
| Ballas, SK | 1 |
| Armstrong, FD | 1 |
| Smith, W | 1 |
| Ataga, K | 1 |
| Swerdlow, P | 1 |
| Kutlar, A | 1 |
| DeCastro, L | 1 |
| Waclawiw, MA | 1 |
| Lê, PQ | 1 |
| Ferster, A | 1 |
| Cotton, F | 1 |
| Vertongen, F | 1 |
| Vermylen, C | 1 |
| Vanderfaeillie, A | 1 |
| Dedeken, L | 1 |
| Heijmans, C | 1 |
| Ketelslegers, O | 1 |
| Dresse, MF | 1 |
| Gulbis, B | 1 |
| Alioglu, B | 1 |
| Demirhan, B | 1 |
| Ozyurek, E | 1 |
| Varan, B | 1 |
| Erbay, A | 1 |
| Ozbek, N | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Evaluation of the Hemostatic Potential in Sickle Cell Disease Patients[NCT02565082] | 64 participants (Actual) | Interventional | 2015-09-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for hydroxyurea and Sepsis
| Article | Year |
|---|---|
The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up.
Topics: Adolescent; Adult; Anemia, Sickle Cell; DNA Damage; Drug Utilization; Early Termination of Clinical | 2010 |
4 other studies available for hydroxyurea and Sepsis
| Article | Year |
|---|---|
The effects of hydroxyurea on proinflammatory cytokine and tissue histopathology in an experimental sepsis model.
Topics: Animals; Cytokines; Hydroxyurea; Inflammation; Rats; Sepsis; Tumor Necrosis Factor-alpha | 2022 |
Atypical CML with massive splenic infarct: an extremely rare presentation.
Topics: Abdominal Pain; Anemia; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Fatal Outcom | 2015 |
Sickle cell disease from Africa to Belgium, from neonatal screening to clinical management.
Topics: Adolescent; Africa; Anemia, Sickle Cell; Antisickling Agents; Belgium; Bone Marrow Transplantation; | 2010 |
Pulmonary hypertension in a child with juvenile myelomonocytic leukemia secondary to pulmonary leukemic cell infiltration.
Topics: Anti-Bacterial Agents; Child, Preschool; Combined Modality Therapy; Diagnostic Errors; Fatal Outcome | 2006 |